Therapeutic Product Immunogenicity Community

 View Only

  • 1.  New AAPS Journal article of possible community interest

    Posted 07-18-2022 18:14
    Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium - The AAPS Journal
    SpringerLink remove preview
    Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium - The AAPS Journal
    During biotherapeutic drug development, immunogenicity is evaluated by measuring anti-drug antibodies (ADAs). The presence and magnitude of ADA responses is assessed using a multi-tier workflow where samples are screened, confirmed, and titered. Recent reports suggest that the assay signal to noise ratio (S/N) obtained during the screening tier correlates well with titer.
    View this on SpringerLink >



    To view the full article through your AAPS membership:

    Go to https://www.aaps.org/education-and-research/journals/the-aaps-journal 

    Enter your AAPS credentials

    Click "Member Access to Journals"

    Click on the The AAPS Journal cover.

    Copy and paste the url into the "Search" box, and click search

    The full article should appear.



    ------------------------------
    Ho-Leung Fung Ph.D., FAAPS
    Editor-in-Chief
    University at Buffalo
    Buffalo NY
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------


  • 2.  RE: New AAPS Journal article of possible community interest

    Posted 07-27-2022 15:15
    Highly encourage all members of our community to read this manuscript and think about ways to implement in their programs (when appropriate). A big thanks to @Marta Starcevic Manning for her leadership!​

    ------------------------------
    Johanna Mora Ph.D.
    Bristol-Myers Squibb
    Princeton NJ
    [email protected]
    ------------------------------

    Original Message